## Contents

**Preface**

**Section 1. Hemostasis Physiology**

- **CHAPTER 1. Coagulation Pathway and Physiology**
  - Introduction
  - Constituents of the Hemostatic System
    - Endothelium
    - Platelets
    - Coagulation Proteins
    - The Extrinsic Pathway and the PT
    - The Intrinsic Pathway and the aPTT
    - The PT and aPTT Pathways
    - Newer Coagulation Model
    - Regulatory Mechanisms
  - Operation of the Hemostasis and Thrombosis Pathway
  - Suggested Reading

- **CHAPTER 2. Platelet Structure and Function**
  - Platelet Production
    - Megakaryocyte Development and Maturation
    - Platelet Production from Megakaryocytes
  - Platelet Structure
    - Surface Glycoproteins and Plasma Membrane
      - Von Willebrand Receptor (GPIb/IX/V)
      - Collagen Receptors (GPVI and GPIa/Ia)
      - Adenosine Diphosphate Receptors
      - Thrombin Receptors (PAR-1 and PAR-4)
      - Thromboxane Receptor and Prostaglandin Receptors
      - Fibrinogen Receptor (GPIIb/IIIa)
  - Platelet Cytoskeleton
  - Platelet Membrane Systems
  - Platelet Granules
    - Alpha Granules
    - Dense Granules
  - Platelet Activation
    - Platelet Adhesion
      - Role of GPIb/IX/V and von Willebrand Factor
      - Role of Collagen Receptors
      - Cytoskeletal Changes
    - Platelet Activation and Granule Release
      - Phospholipase Pathway
      - Cyclooxygenase Pathway
      - Platelet Granule Release
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet Aggregation</td>
<td>25</td>
</tr>
<tr>
<td>Platelet Procoagulant Activity</td>
<td>26</td>
</tr>
<tr>
<td>Suggested Reading</td>
<td>26</td>
</tr>
<tr>
<td><strong>CHAPTER 3. Fibrinolytic System Physiology</strong></td>
<td>29</td>
</tr>
<tr>
<td>History</td>
<td>29</td>
</tr>
<tr>
<td>Proteins and Function</td>
<td>29</td>
</tr>
<tr>
<td>Regulation of Fibrinolysis</td>
<td>32</td>
</tr>
<tr>
<td>Fibrinolysis at the Site of a Thrombus</td>
<td>33</td>
</tr>
<tr>
<td>Suggested Reading</td>
<td>34</td>
</tr>
<tr>
<td><strong>Section 2. Basics of Laboratory Testing in Hemostasis</strong></td>
<td>35</td>
</tr>
<tr>
<td><strong>CHAPTER 4. Sample Collection and Processing</strong></td>
<td>37</td>
</tr>
<tr>
<td>Introduction</td>
<td>37</td>
</tr>
<tr>
<td>Sample Collection Technique for Peripheral Venipuncture</td>
<td>37</td>
</tr>
<tr>
<td>Needle Selection for Venipuncture</td>
<td>38</td>
</tr>
<tr>
<td>Tourniquet Effect</td>
<td>38</td>
</tr>
<tr>
<td>Collection Sets</td>
<td>38</td>
</tr>
<tr>
<td>Specimen Labeling</td>
<td>38</td>
</tr>
<tr>
<td>Blood Collection from Indwelling Lines and Catheters</td>
<td>39</td>
</tr>
<tr>
<td>Blood Collection Tubes and Anticoagulant Considerations</td>
<td>39</td>
</tr>
<tr>
<td>Blood Collection Tubes</td>
<td>39</td>
</tr>
<tr>
<td>Blood Tube Draw Order</td>
<td>40</td>
</tr>
<tr>
<td>Anticoagulant</td>
<td>40</td>
</tr>
<tr>
<td>Volume Effect</td>
<td>40</td>
</tr>
<tr>
<td>Hematocrit Effect</td>
<td>41</td>
</tr>
<tr>
<td>Sample Processing</td>
<td>42</td>
</tr>
<tr>
<td>Preparation of Platelet-Poor Plasma</td>
<td>42</td>
</tr>
<tr>
<td>Effects of Temperature and Time</td>
<td>42</td>
</tr>
<tr>
<td>Factors Affecting Specimen Quality</td>
<td>44</td>
</tr>
<tr>
<td>Suggested Reading</td>
<td>45</td>
</tr>
<tr>
<td><strong>CHAPTER 5. Clinical History in Hemostasis</strong></td>
<td>47</td>
</tr>
<tr>
<td>Introduction</td>
<td>47</td>
</tr>
<tr>
<td>Clinical History in Bleeding Patients</td>
<td>47</td>
</tr>
<tr>
<td>Determine Whether the Patient Has Excess Bleeding</td>
<td>47</td>
</tr>
<tr>
<td>Extent of Bleeding</td>
<td>47</td>
</tr>
<tr>
<td>Duration of Bleeding Abnormality</td>
<td>49</td>
</tr>
<tr>
<td>Type of Bleeding</td>
<td>49</td>
</tr>
<tr>
<td>Bleeding Due to Vascular Disorders</td>
<td>50</td>
</tr>
<tr>
<td>Posttraumatic and Spontaneous Bleeding</td>
<td>50</td>
</tr>
<tr>
<td>Hemarthrosis and Hematomas</td>
<td>50</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>50</td>
</tr>
<tr>
<td>Surgical Procedures</td>
<td>50</td>
</tr>
<tr>
<td>Gingival/Dental Bleeding History</td>
<td>51</td>
</tr>
<tr>
<td>Menstrual History</td>
<td>51</td>
</tr>
<tr>
<td>Obstetric History</td>
<td>51</td>
</tr>
<tr>
<td>Bleeding Due to Organ System Disorders</td>
<td>51</td>
</tr>
<tr>
<td>Medication and Food Habits</td>
<td>52</td>
</tr>
<tr>
<td>Family History</td>
<td>53</td>
</tr>
<tr>
<td>Previous Coagulation Test Results</td>
<td>54</td>
</tr>
<tr>
<td>Pediatric Considerations</td>
<td>54</td>
</tr>
<tr>
<td>Clinical History in Patient with Thrombosis</td>
<td>54</td>
</tr>
<tr>
<td>Age of Onset</td>
<td>55</td>
</tr>
</tbody>
</table>
Ethnicity 55
Location and Type of Thrombosis (Venous, Arterial, or Embolic) 57
Recurrences 57
Acquired Thrombophilic Risk Factors 57
Medical History 57
Malignancy 58
Obstetrical History and Hormone Therapy 58
Medication History 59
Surgery and Trauma 59
Elevated Levels of Homocysteine 59
Summary 59
Suggested Reading 59

CHAPTER 6. Coagulation Testing 63
Introduction 63
Laboratory Measurement of Clot-Based Coagulation Tests 63
Coagulation Analyzers 63
Principles of Performance 63
How to Select and Validate a Coagulation Analyzer 64
Prothrombin Time 64
Reagent Considerations 65
Reporting of Prothrombin Time 66
Calculation of International Normalized Ratio 66
Clinical Utility of Prothrombin Time 70
Point-of-Care Monitors for Oral Anticoagulant Therapy 70
Activated Partial Thromboplastin Time 70
Principle 70
Reagents 71
Method 71
Reference Range 71
Clinical Utility of Activated Partial Thromboplastin Time 71
Steps to Take in the Evaluation of a Prolonged Activated Partial Thromboplastin Time 72
Evaluation of Unfractionated Heparin Sensitivity 72
Thrombin Time 73
Method 73
Reagents 73
Reference Ranges 73
Clinical Utility of Thrombin Time 73
Fibrinogen Assay 74
Clinical Utility of Fibrinogen Assays 75
Assay of Specific Factors 75
Principle 75
Factor II (Prothrombin) 76
Factors V, VII, and X 76
Factors VIII, IX, XI, and XII, and High-Molecular-Weight Kininogen and Prekallikrein 76
False-Positives and False-Negatives in Factor Assays 77
Factor XIII 77
Von Willebrand Factor 78
Mixing Studies 78
Principle 78
Technical Considerations 78
Procedure 80
Criteria for Interpretation of Mixing Studies 80
Specific Inhibitor Studies 80
Bethesda Assay 80
Nijmegen Modification 81
Reporting of Results 81
Establishing Reference Ranges and Validating Coagulation Laboratory Testing 82
Preanalytic and Postanalytic Considerations 82
Reference Range 82
Accuracy 82
Precision 83
Linearity 83
Interfering Conditions 83
Quality Control 85
Frequency of QC Testing 86
Results Reporting 87
Turnaround Time 87
Reporting of Results 87
Quality Assurance 88
External Proficiency Testing 88
Summary 89
Suggested Reading 89

CHAPTER 7. Platelet Testing 93
Patient History 93
Clinical History for Patients with a Bleeding Diathesis 93
Clinical History for Patients with Thrombosis 93
Platelet Count, Indices, and Morphology 94
Sample Collection and Processing Considerations 94
Test Performance and Interpretation 95
Bone Marrow Analysis 96
Sample Collection and Processing Considerations 96
Bone Marrow Interpretation 97
Platelet Function Testing 97
Bleeding Time 98
PFA-100 98
Specimen Considerations 98
Test Performance and Interpretation 98
Platelet Aggregation 101
Specimen Considerations 101
Test Performance and Interpretation 101
Plateletworks 103
VerifyNow 104
Release Assays 105
Lumiaggregation 105
Release Markers 106
P-selectin 106
Adhesion Assays 106
Platelet Adhesion Chambers 106
Impact 106
Platelet Mechanical Assays 106
Hemostasis Analysis System 106
Whole Blood Viscoelastometry 107
Flow Cytometry 107
Platelet Turnover (Platelet Reticulocyte Analysis) 109
Electron Microscopy 109
CHAPTER 11. Prolonged Prothrombin Time

Introduction

Differential Diagnosis of a Corrected Mixing Study

- Dilutional Coagulopathy
- Disseminated Intravascular Coagulation
- Drugs

- Warfarin
- Factor Deficiency

- Factor II Deficiency
- Factor V Deficiency
- Factor V and Factor VIII Deficiency, Combined
- Factor VII Deficiency
- Factor X Deficiency
- Fibrinogen Deficiency
- Vitamin K-Dependent Coagulation Factor Deficiency, Hereditary

- Liver Disease
- Superwarfarin Poisoning
- Vitamin K Deficiency

- Newborns
- Adults

Differential Diagnosis of a Noncorrected Mixing Study

- Drugs

- Direct Thrombin Inhibitors
- Heparin
- Factor Inhibitors

- Factor II Inhibitor
- Factor V Inhibitor
- Factor VII Inhibitor
- Factor X Inhibitor

- Lupus Anticoagulant

Algorithm

Suggested Reading

Case Studies: Prolonged PT with Normal aPTT; Prolonged PT with Prolonged aPTT

CHAPTER 12. Normal Prothrombin Time and Activated Partial Thromboplastin Time

Introduction

Clinical Evaluation
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>False-Negative (Normal) PT and aPTT</td>
<td>169</td>
</tr>
<tr>
<td>Patient-Specific Causes</td>
<td>170</td>
</tr>
<tr>
<td>Preanalytic Causes</td>
<td>170</td>
</tr>
<tr>
<td>Analytic Causes</td>
<td>170</td>
</tr>
<tr>
<td>Postanalytic Causes</td>
<td>171</td>
</tr>
<tr>
<td>Additional Testing</td>
<td>171</td>
</tr>
<tr>
<td>Primary Hemostasis Defects</td>
<td>171</td>
</tr>
<tr>
<td>Secondary Hemostasis Defects</td>
<td>171</td>
</tr>
<tr>
<td>Factor Assays</td>
<td>171</td>
</tr>
<tr>
<td>Factor XIII Deficiency</td>
<td>171</td>
</tr>
<tr>
<td>Fibrinolysis Defects</td>
<td>172</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td>172</td>
</tr>
<tr>
<td>Algorithm</td>
<td>173</td>
</tr>
<tr>
<td>Suggested Reading</td>
<td>173</td>
</tr>
<tr>
<td><strong>Case Study</strong></td>
<td>170</td>
</tr>
<tr>
<td><strong>Chapter 13. Fibrinolytic Bleeding Disorders</strong></td>
<td>175</td>
</tr>
<tr>
<td>Clinical Evaluation of Fibrinolytic Bleeding Disorders</td>
<td>175</td>
</tr>
<tr>
<td>Plasminogen Activator Inhibitor-1 Deficiency</td>
<td>175</td>
</tr>
<tr>
<td>Alpha-2 Antiplasmin Deficiency</td>
<td>177</td>
</tr>
<tr>
<td>Acquired Causes of Fibrinolytic Bleeding</td>
<td>177</td>
</tr>
<tr>
<td>Disseminated Intravascular Coagulation</td>
<td>178</td>
</tr>
<tr>
<td>Suggested Reading</td>
<td>182</td>
</tr>
<tr>
<td><strong>Case Study: Postoperative Bleeding and PAI-1 Deficiency</strong></td>
<td>175</td>
</tr>
<tr>
<td><strong>Case Study: Tissue Plasminogen Activator Release During Renal Transplantation</strong></td>
<td>177</td>
</tr>
<tr>
<td><strong>Case Study: DIC Associated with Gastric Carcinoma</strong></td>
<td>178</td>
</tr>
<tr>
<td><strong>Chapter 14. Platelet Disorders</strong></td>
<td>185</td>
</tr>
<tr>
<td>Introduction</td>
<td>185</td>
</tr>
<tr>
<td>Platelet Dysfunction with Normal Platelet Count (Qualitative Platelet Disorders)</td>
<td>185</td>
</tr>
<tr>
<td>Glycoprotein Disorders</td>
<td>189</td>
</tr>
<tr>
<td>Glanzmann Thrombasthenia (GPIIb/IIIa Deficiency)</td>
<td>189</td>
</tr>
<tr>
<td>Glycoprotein Ib/IX/V (Bernard-Soulier Syndrome)</td>
<td>190</td>
</tr>
<tr>
<td>Platelet-Type von Willebrand Disease</td>
<td>190</td>
</tr>
<tr>
<td>Glycoprotein IV</td>
<td>191</td>
</tr>
<tr>
<td>Collagen Receptor Disorders (GPIa/IIa and GPVI)</td>
<td>191</td>
</tr>
<tr>
<td>Adenosine Diphosphate Receptor Abnormalities</td>
<td>191</td>
</tr>
<tr>
<td>Platelet Release Defects</td>
<td>191</td>
</tr>
<tr>
<td>Storage Pool Disorders (Alpha and Dense Granule Disorders)</td>
<td>191</td>
</tr>
<tr>
<td>Signal Transduction Disorders</td>
<td>194</td>
</tr>
<tr>
<td>Disorders of Platelet Procoagulant Activity (Scott Syndrome)</td>
<td>195</td>
</tr>
<tr>
<td>Platelet Disorders with Thrombocytosis</td>
<td>195</td>
</tr>
<tr>
<td>Reactive Thrombocytosis</td>
<td>195</td>
</tr>
<tr>
<td>Myeloproliferative Disorders Associated with Thrombocytosis</td>
<td>196</td>
</tr>
<tr>
<td>Platelet Disorders with Thrombocytopenia</td>
<td>196</td>
</tr>
<tr>
<td>Thrombocytopenia with Increased Platelet Size</td>
<td>197</td>
</tr>
<tr>
<td>Macrothrombocytopenias with Neutrophilic Inclusions (MYH9 Disorders)</td>
<td>197</td>
</tr>
<tr>
<td>Bernard-Soulier Syndrome</td>
<td>199</td>
</tr>
<tr>
<td>The Gray Platelet Syndrome (Alpha Granule Storage Pool Disorder)</td>
<td>200</td>
</tr>
<tr>
<td>Thrombocytopenia with Decreased Platelet Size</td>
<td>201</td>
</tr>
<tr>
<td>Wiskott-Aldrich Syndrome and X-Linked Thrombocytopenia</td>
<td>201</td>
</tr>
<tr>
<td>Thrombocytopenia with Normal Platelet Size</td>
<td>201</td>
</tr>
<tr>
<td>Peripheral Platelet Destruction</td>
<td>202</td>
</tr>
<tr>
<td>Immune Destructive Thrombocytopenias</td>
<td>202</td>
</tr>
</tbody>
</table>
Nonimmune Destructive Thrombocytopenias 204
Decreased Platelet Production 207
Hereditary Thrombocytopenias with Decreased Platelet Production 207
Acquired Thrombocytopenias with Decreased Platelet Production 208
Platelet Dysfunction Associated with Other Illnesses 208
Platelet Disorders Associated with Thrombosis or Platelet Activation 208
Platelet Activation 209
Genetic Polymorphisms Associated with Thrombosis and Cardiovascular Disease 209
Cardiovascular Devices 210
Summary 210
Suggested Reading 211
Case Study 185

CHAPTER 15. Abnormal Thrombin Time 217
Introduction 217
Clinical Indications 217
Differential Diagnosis 218
Amyloidosis 218
Autoantibodies 219
Drugs 219
  Bovine Thrombin, Topical 219
  Direct Thrombin Inhibitors 219
  Heparin 219
  Plasminogen Activators 220
  Volume Expanders 220
Fibrin Degradation Products 220
Fibrinogen Abnormalities 220
  Dysfibrinogenemia 220
  Hypofibrinogenemia 222
  A fibrinogenemia 222
  Hyperfibrinogenemia 222
  Radiocontrast Agents 222
Algorithm 222
Suggested Reading 222
Case Study 217

CHAPTER 16. Von Willebrand Disease 225
Introduction 225
Von Willebrand Factor 225
Clinical Features 225
  Classification 226
  Inheritance 227
Laboratory Testing 227
  Laboratory Findings in Type 1 von Willebrand Disease 230
  Laboratory Findings in Type 2 von Willebrand Disease 230
  Laboratory Findings in Type 3 von Willebrand Disease 231
The Molecular Basis of von Willebrand Disease 231
Acquired von Willebrand Disease 232
Treatment 233
Suggested Reading 234

Section 4. Algorithmic Approach to Thrombophilic Disorders 237

CHAPTER 17. Arterial and Venous Thrombosis in Adults 239
Introduction 239
General Considerations 240
Consent and Counseling 240
Assay Calibration, Reference Range, and Assay Reliability 240
Combined Deficiency 241
Testing for Thrombophilic Risk in Patients with Venous or Arterial Thrombosis 241
Venous Thromboembolism 241
What Tests Should Be Performed? 242
When Should Thrombophilia Testing Be Performed? 244
Recommendations for Testing of Individual Analytes 244
Protein C, Protein S, and Antithrombin Deficiency 244
Factor V Leiden and Prothrombin G20210A Mutations 245
Hyperhomocysteinemia and High Concentrations of Factor VIII 246
Acquired Thrombophilic Risk Factors 246
Antiphospholipid Antibodies 246
Heparin-Induced Thrombocytopenia 246
Thrombophilic Risk Factor Test Selection in Arterial Thrombosis 247
Antiphospholipid Antibodies (Lupus Anticoagulant and Anticardiolipin Antibodies) 248
C-Reactive Protein 248
Lipoprotein (a) 248
Homocysteine 249
Prothrombin G20210A Mutation 250
Factor V Leiden (Activated Protein C Resistance) 250
Deficiencies of Protein C, Protein S, and Antithrombin 250
Coagulation Factors 251
Heparin-Induced Thrombocytopenia 251
Thrombophilic Risk Factor Test Selection in Neurovascular Thrombosis 251
Antiphospholipid Antibodies (Lupus Anticoagulant and Anticardiolipin Antibodies) 251
Lipoprotein (a) 251
Homocysteine 252
Prothrombin G20210A Mutation 253
Factor V Leiden (Activated Protein C Resistance) 253
Deficiencies of Protein C, Protein S, and Antithrombin 253
Heparin-Induced Thrombocytopenia 254
Suggested Reading 254
Case Studies 242

CHAPTER 18. Unique Issues of Thrombophilia in Women and Children 257
Introduction 257
Pregnancy and Hormonal Therapy 257
Oral Contraceptives and Risk of Venous Thromboembolism 257
Hormone Replacement Therapy and Venous Thromboembolism 258
Pregnancy-Related Venous Thromboembolism 259
Thrombophila and Recurrent Fetal Loss 259
Thrombophilia and Late Gestational Vascular Complications 260
Treatment of Pregnant Women with Thrombophilias 261
Thrombophilia in Neonates, Infants, and Children 262
Description of the Problem 262
Testing for Thrombophilia in Children 263
Suggested Reading 265
Case Study 258
Case Study 262
CHAPTER 19. Laboratory Diagnosis of Inherited Thrombophilia 267

Introduction 267
Algorithmic Approach to Laboratory Diagnosis of Thrombophilic Risk Factors
  Protein C 268
  Protein S 270
  Antithrombin 271
  Factor VIII 272
  Activated Protein C Resistance and Factor V Leiden 273
  Prothrombin G20210A Mutation 274
  Homocysteine 274

Thrombophilia Testing, Duration of Anticoagulation Therapy, and Screening First-Degree Relatives 274
Suggested Reading 277
Case Study 268

CHAPTER 20. Fibrinolytic Thrombotic Disorders 279

Introduction 279
Thrombosis and Defects of Fibrinolysis 279
  Plasminogen Deficiency 279
  Tissue Plasminogen Activator Deficiency 279
  Plasminogen Activator Inhibitor Excess 280
  Alpha 2-Antiplasmin Excess 280
  Euglobulin Clot Lysis Time Assay 280
  Thrombin-Activatable Fibrinolysis Inhibitor 280
  Dysfibrinogenemia 281
  Factor XII (Hageman Factor) Deficiency 281
  Lipoprotein (a) Excess 281
  Disseminated Intravascular Coagulation 281
  Antifibrinolytic Medications 282
The Role of D-dimer in Excluding Venous Thromboembolism 282
  D-Dimer Testing 283
    Variations in the Types of D-Dimer Assays 283
    Selecting the Appropriate Cutoff and Units for Excluding Venous Thromboembolism 284
Summary 284
Suggested Reading 284
Case Study 282

CHAPTER 21. Heparin-Induced Thrombocytopenia 287

Introduction 287
Clinical Presentation 287
Pathophysiology 289
Clinical Laboratory Diagnosis and Algorithm 289
Treatment 292
Suggested Reading 293
Case Study 287

CHAPTER 22. Antiphospholipid Antibodies 295

Introduction 295
Laboratory Testing for Antiphospholipid Antibodies 295
  Lupus Anticoagulant Testing Considerations and International Society on Thrombosis and Haemostasis (ISTH) Criteria 295
    Preanalytical Variables 297
    Testing for a Lupus Anticoagulant 297
    Exclusion of Other Abnormalities (Factor Inhibitors) 300
    Indeterminate Results: When Samples Do Not Meet All International Society on Thrombosis and Haemostasis Criteria 301
Section 5. Antiplatelet and Anticoagulant Drugs

CHAPTER 23. Antithrombotic Agents
Introduction
Target Therapeutic Range and Monitoring Considerations
Common Clinical Settings Where Antithrombotic Agents Are Used
  Acute Venous Thromboembolism
  Prophylaxis for Venous Thromboembolism
  Prophylaxis in Patients with Atrial Fibrillation
  Acute Coronary Syndromes
  Peripheral Vascular and Cerebrovascular Disease
  Extracorporeal Circulation
  Implantation of Mechanical Heart Valves
Effects on Tests of Hemostasis
Summary
Suggested Reading

CHAPTER 24. Anticoagulant Agents
Introduction
Unfractionated Heparin
  Laboratory Monitoring of Unfractionated Heparin
    Acute Venous Thromboembolism
    Acute Coronary Syndromes
    Renal Dialysis, Percutaneous Coronary Intervention, and Cardiopulmonary Bypass
Low-Molecular-Weight Heparins
  Laboratory Monitoring of Low-Molecular-Weight Heparin
Fondaparinux
  Laboratory Monitoring of Fondaparinux
Hirudins (Peptide Direct Thrombin Inhibitors)
  Laboratory Monitoring of Hirudin Analogues
Argatroban
  Laboratory Monitoring of Argatroban
Oral Anticoagulants
  Laboratory Monitoring of Vitamin K Antagonists
Suggested Reading

CHAPTER 25. Antiplatelet Agents
Introduction
Parenteral Agents
  Glycoprotein IIb/IIIa Inhibitors
    Mechanism of Action
    Effect on Platelet Function Tests
    Clinical Uses
    Role of Monitoring
    Special Issues
Oral Agents
  Aspirin
    Mechanism of Action
    Clinical Uses
Laboratory Tests Used to Assess Effect 338
Laboratory Monitoring 339
Thienopyridines 340
Mechanism of Action 340
Clinical Uses 341
Laboratory Monitoring 342
Clotidogrel Resistance 342
Dipyridamole 342
Mechanism of Action 342
Clinical Uses 343
Monitoring Issues 343
Iloprost 344
Cilostazol 344
Mechanism of Action 344
Clinical Uses 344
Monitoring Issues 344
New Antiplatelet Drugs in Development 344
Antiplatelet Effect of Other Drugs and Herbal Remedies 345
Summary 346
Suggested Reading 346

Section 6. Appendices and Index 353
Appendix A. Abbreviations 355
Appendix B. Example Reference Ranges 359
Index 361

List of Algorithms
Detection of Interfering Drug Effects Prior to Performing aPTT Mixing Studies 79
Platelet Functional Analyzer-100 (PFA-100) Testing 99
Thrombophilia Risk Factor Screening 126
Evaluation of a Prolonged aPTT 148
Evaluation of Slight Prolongation of the aPTT 149
Investigation of a Prolonged PT with or without a Prolonged aPTT 163
Diagnosis of a Bleeding Etiology with a Normal PT and aPTT 172
Use of D-Dimer Assay to Assess DIC 180
Distinguishing Platelet Abnormalities with a Normal or Increased Platelet Count 187
Platelet Aggregation Studies to Distinguish Between Acquired Platelet Disorders 187
Distinction of Platelet Disorders with Thrombocytopenia with Increased or Decreased Platelet Size 197
Diagnosis of Thrombocytopenic Disorders Associated with Increased Platelet Destruction or Decreased Production 202
Evaluation of an Abnormal Thrombin Time 221
Inherited Thrombophilia Testing 244
Inherited Thrombophilia Risk Factor Confirmatory Testing 267
Protein C Testing 269
Protein S Testing 270
Antithrombin Testing 272
Activated Protein C Resistance/Factor V Leiden Testing 273
Homocysteine Testing 275
Diagnosis of Heparin-Induced Thrombocytopenia, Typical Onset 290
Diagnosis of Heparin-Induced Thrombocytopenia, Rapid Onset 291
Diagnosis of the Presence of a Lupus Anticoagulant 298